How about you do your own research. It's not so hard to go to the Curis website and count the number of trials. You do know how to count? Stop being a lazy do nothing loser. This message board has managed to get even more pathetic in my absence. No worries, I am back and I will be flushing out the garbage.
Wow on top of being a rude #$%$ you are also clearly incompetent. Pretty obvious that he was being sarcastic and eluding to the fact that this one drug is only one of many things that Curis has in its pipeline, the most significant right now being its operable BCC results which should be out in early 2014.
This company doesn't suffer from a lack of potential, and it has a nice cash cow with erivedge, a drug that fills a unique niche in the industry. It's all the weak hands and poor share holder loyalty that hurts it.